Cargando…

Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors

A new series of homosulfocoumarins (3H-1,2-benzoxathiepine 2,2-dioxides) possessing various substitution patterns and moieties in the 7, 8 or 9 position of the heterocylic ring were prepared by original procedures and investigated for the inhibition of four physiologically relevant carbonic anhydras...

Descripción completa

Detalles Bibliográficos
Autores principales: Pustenko, Aleksandrs, Nocentini, Alessio, Balašova, Anastasija, Alafeefy, Ahmed, Krasavin, Mikhail, Žalubovskis, Raivis, Supuran, Claudiu T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896485/
https://www.ncbi.nlm.nih.gov/pubmed/31790605
http://dx.doi.org/10.1080/14756366.2019.1695795
_version_ 1783476788843773952
author Pustenko, Aleksandrs
Nocentini, Alessio
Balašova, Anastasija
Alafeefy, Ahmed
Krasavin, Mikhail
Žalubovskis, Raivis
Supuran, Claudiu T.
author_facet Pustenko, Aleksandrs
Nocentini, Alessio
Balašova, Anastasija
Alafeefy, Ahmed
Krasavin, Mikhail
Žalubovskis, Raivis
Supuran, Claudiu T.
author_sort Pustenko, Aleksandrs
collection PubMed
description A new series of homosulfocoumarins (3H-1,2-benzoxathiepine 2,2-dioxides) possessing various substitution patterns and moieties in the 7, 8 or 9 position of the heterocylic ring were prepared by original procedures and investigated for the inhibition of four physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isoforms, the human (h) hCA I, II, IX and XII. The 8-substituted homosulfocoumarins were the most effective hCA IX/XII inhibitors followed by the 7-substituted derivatives, whereas the substitution pattern in position 9 led to less effective binders for the transmembrane, tumour-associated isoforms IX/XII. The cytosolic isoforms hCA I and II were not inhibited by these compounds, similar to the sulfocoumarins/coumarins investigated earlier. As hCA IX and XII are validated anti-tumour targets, with one sulphonamide (SLC-0111) in Phase Ib/II clinical trials, finding derivatives with better selectivity for inhibiting the tumour-associated isoforms over the cytosolic ones, as the homosulfocoumarins reported here, is of crucial importance.
format Online
Article
Text
id pubmed-6896485
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-68964852019-12-13 Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors Pustenko, Aleksandrs Nocentini, Alessio Balašova, Anastasija Alafeefy, Ahmed Krasavin, Mikhail Žalubovskis, Raivis Supuran, Claudiu T. J Enzyme Inhib Med Chem Research Paper A new series of homosulfocoumarins (3H-1,2-benzoxathiepine 2,2-dioxides) possessing various substitution patterns and moieties in the 7, 8 or 9 position of the heterocylic ring were prepared by original procedures and investigated for the inhibition of four physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isoforms, the human (h) hCA I, II, IX and XII. The 8-substituted homosulfocoumarins were the most effective hCA IX/XII inhibitors followed by the 7-substituted derivatives, whereas the substitution pattern in position 9 led to less effective binders for the transmembrane, tumour-associated isoforms IX/XII. The cytosolic isoforms hCA I and II were not inhibited by these compounds, similar to the sulfocoumarins/coumarins investigated earlier. As hCA IX and XII are validated anti-tumour targets, with one sulphonamide (SLC-0111) in Phase Ib/II clinical trials, finding derivatives with better selectivity for inhibiting the tumour-associated isoforms over the cytosolic ones, as the homosulfocoumarins reported here, is of crucial importance. Taylor & Francis 2019-12-02 /pmc/articles/PMC6896485/ /pubmed/31790605 http://dx.doi.org/10.1080/14756366.2019.1695795 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Pustenko, Aleksandrs
Nocentini, Alessio
Balašova, Anastasija
Alafeefy, Ahmed
Krasavin, Mikhail
Žalubovskis, Raivis
Supuran, Claudiu T.
Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors
title Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors
title_full Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors
title_fullStr Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors
title_full_unstemmed Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors
title_short Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors
title_sort aryl derivatives of 3h-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896485/
https://www.ncbi.nlm.nih.gov/pubmed/31790605
http://dx.doi.org/10.1080/14756366.2019.1695795
work_keys_str_mv AT pustenkoaleksandrs arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors
AT nocentinialessio arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors
AT balasovaanastasija arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors
AT alafeefyahmed arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors
AT krasavinmikhail arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors
AT zalubovskisraivis arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors
AT supuranclaudiut arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors